The round was led by Claudio Del
Vecchio and joined by Bruker Corporation.
NEW YORK, July 20, 2022 /PRNewswire/ -- Acuamark
Diagnostics ("AcuamarkDx"), an early cancer detection company,
today announced the closing of an $11.3
million Series A round.
The round was led by the office of Claudio Del Vecchio and the Del Vecchio Family
Foundation, and it was joined by Bruker Corporation as a new
investor in AcuamarkDx. Claudio Del
Vecchio has joined AcuamarkDx's Board of Directors.
AcuamarkDx is a molecular diagnostics company that develops
ultra-sensitive, automatable technology, designed for both more
reliable and more cost-effective early-cancer detection, ultimately
to save lives on a vast scale and reduce health-inequities in
cancer care globally.
Bruker Corporation (NASDAQ: BRKR), which also contributed to
Series A, is a global life-science tool and diagnostics
instrumentation company, with a particular interest in early cancer
detection.
"We are grateful for our investors' confidence and the
sophisticated financial and technical depth they bring to our
work," says co-founder and CEO Dr. Bernard Peperstraete, "After years of
innovation and development, we are pleased with the progress of our
assays. We are hard at work to continue the optimization of the
assay while initiating larger scale clinical collections."
With the Series A proceeds, Acuamark Diagnostics intends to
scale its sample collections and add a number of key building
blocks to its organization.
"As an investor prior to this round, I closely monitored the
company's remarkable work to improve early-cancer interception and
make it broadly accessible," says investor Mr. Del Vecchio. "With successful development and
at the industrial scale the technology is designed for, AcuamarkDx
will be in a highly differentiated position to help benefit our
society, saving lives, yet with large, systemic cost savings as a
consequence. I look forward to working closely with Bernard and the
Board of Directors to help make the vision a reality and move the
company to the next level."
Mr. William Gedale, Executive
Chairman, comments: "We are honored to welcome a Director of the
skill and character of Mr. Del
Vecchio. Claudio is a proven executive and successful
investor in a wide range of businesses globally. We warmly
welcome him to our group of committed Board members and
colleagues."
"Mr. Del Vecchio
combines a salt-of-the-earth humanity with an innate understanding
of building extra-ordinary value. He adds a wealth of wisdom and
public governance experience to our Board," Dr. Peperstraete
adds.
About Claudio Del Vecchio, PhD
Claudio Del Vecchio is an
international business entrepreneur and industry leader. He is a
skilled executive and a seasoned public Board member. The
Del Vecchio family founded the
Luxottica Group where Mr. Del
Vecchio was an Executive Board Director for several years,
ran its US operations, and oversaw its public offering on the New
York Stock Exchange. Subsequently, Mr. Del
Vecchio acquired Brooks Brothers which he successfully ran
for 20 years until the COVID Pandemic.
About Acuamark Diagnostics
Inc.
Acuamark Diagnostics is a biotechnology company focused on
developing innovative technology for improved and cost-effective
blood-based early-cancer screening for single cancer early
detection and multi-cancer early detection. Backed by a highly
experienced team of industry developers and scientific experts, it
is AcuamarkDx's mission to improve cancer management and increase
survival by intercepting early-cancer more reliably, accessibly,
and cost-effectively with its first-in-kind, high-throughput
precision technology.
For more information, please visit www.acuamarkdx.com, or
contact us at info@acuamarkdx.com.
Contact:
Acuamark Diagnostics, Inc.
101 Avenue Of the Americas, Fl 3, JLabs
New York, NY, 10013
USA
info@acuamarkdx.com